Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 15

Trial Status

Completed3
Terminated1
Other1

Role Distribution

Principal Investigator5
PI Rate100%

Activity Timeline

Clinical Trials (5)

NCT03435952Phase 1Active Not Recruiting
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
Malignant Neoplasm of BreastMalignant Neoplasms of Digestive OrgansMalignant Neoplasms of Eye Brain and Other Parts of Central Nervous System+9 more
PrincipalinvestigatorStart date: 2018-07-10
NCT01582191Phase 1Completed
Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer
Advanced Malignant NeoplasmMetastatic Malignant NeoplasmRecurrent Malignant Neoplasm+1 more
PrincipalinvestigatorStart date: 2012-05-14
NCT01548144Phase 1Terminated
Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer
Advanced Cancers
PrincipalinvestigatorStart date: 2012-04-01
NCT01143779Phase 1Completed
FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib
Advanced Cancer
PrincipalinvestigatorStart date: 2010-06-01
NCT00610493Phase 1Completed
Bevacizumab and Temsirolimus in Patients With Advanced Malignancy
Advanced Cancer
PrincipalinvestigatorStart date: 2008-01-25

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Lin Shen, MD

Peking University Cancer Hospital & Institute

Related
20 trials

Shared therapeutic areas:

Advanced CancerAdvanced Malignant NeoplasmBreast Cancer
Similarity Score5%

Lizhi Niu, PhD

Fuda Cancer Hospital

Related
31 trials

Shared therapeutic areas:

Breast Cancer
Similarity Score2%

Herui Yao, PhD

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Related
11 trials

Shared therapeutic areas:

Breast Cancer
Similarity Score2%

Dong-Xin Wang, MD, PhD

Peking University First Hospital

Related
74 trials

Shared therapeutic areas:

Breast Cancer
Similarity Score2%

Ali MA Ismail, lecturer

Cairo University

Related
27 trials

Shared therapeutic areas:

Breast Cancer
Similarity Score2%

Areej El-Jawahri, MD

Massachusetts General Hospital

Related
21 trials

Shared therapeutic areas:

Advanced Cancer

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score2%

Steven A Rosenberg, M.D.

National Cancer Institute (NCI)

Related
32 trials

Shared therapeutic areas:

Breast Cancer

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score2%

John D. Hainsworth, MD

SCRI Development Innovations, LLC

Related
26 trials

Shared therapeutic areas:

Breast Cancer
Similarity Score2%

Aminah Jatoi, MD

Mayo Clinic

Related
29 trials

Shared therapeutic areas:

Breast Cancer

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score2%

Jamie Ostroff, PhD

Memorial Sloan Kettering Cancer Center

Related
17 trials

Shared therapeutic areas:

Breast Cancer

Worked with same sponsors:

M.D. Anderson Cancer CenterNational Cancer Institute (NCI)
Similarity Score2%

Publications (0)

No publications found for this investigator.

Clinical Trials (5)

Showing 5 of 5 trials

NCT03435952Phase 1PrincipalInvestigator

Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT

Malignant Neoplasm of BreastMalignant Neoplasms of Digestive OrgansMalignant Neoplasms of Eye Brain and Other Parts of Central Nervous System+9 more
Active Not Recruiting
NCT01582191Phase 1PrincipalInvestigator

Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer

Advanced Malignant NeoplasmMetastatic Malignant NeoplasmRecurrent Malignant Neoplasm+1 more
Completed
NCT01548144Phase 1PrincipalInvestigator

Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer

Advanced Cancers
Terminated
NCT01143779Phase 1PrincipalInvestigator

FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib

Advanced Cancer
Completed
NCT00610493Phase 1PrincipalInvestigator

Bevacizumab and Temsirolimus in Patients With Advanced Malignancy

Advanced Cancer
Completed

All 5 trials loaded